Beigene Ltd ADR (NQ: BGNE )
236.90 +9.17 (+4.03%) Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
All News about Beigene Ltd ADR
BeiGene to Present at Upcoming Investor Conferences
May 24, 2023
Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis
May 22, 2023
Immix Biopharma Inc's (NASDAQ: IMMX) subsidiary Nexcella Inc announced updated AL Amyloidosis clinical data from its ongoing Phase 1b/2a NEXICART-1 study of its BCMA-targeted chimeric antigen receptor...
Recap: BeiGene Q1 Earnings
May 04, 2023
BeiGene Earnings Perspective: Return On Capital Employed
March 02, 2023
SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023
April 17, 2023
MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023
April 17, 2023
Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow
April 11, 2023
A surge in oncology drug development, coupled with increased patient access and early diagnosis, has resulted in a massive increase in global spending on cancer treatments. Due to this, the global...
Silicon Valley Bank Collapse Might Have Limited Impact On Asia, But Confidence Seems Shaken
March 13, 2023
Some Asian firms have disclosed cash deposits at troubled U.S. lender Silicon Valley Bank (NASDAQ: SIVB), known for its deep ties with the healthcare and tech sector. Most emphasized that the amounts...
BeiGene Reports Fourth Quarter and Full Year 2022 Financial Results
February 27, 2023
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following